一種新型多鏈接系統(tǒng)允許最多3臺血液學(xué)分析儀連接到同一臺驗證工作站，使得單個血液學(xué)實驗室經(jīng)過設(shè)置，每天可以處理2000個樣本。

這套系統(tǒng)叫做ABX Pentra ML，設(shè)計與Horiba ABX血液學(xué)分析儀配套使用。ABX Pentra ML允許該公司任何型號的ABX Pentra或者Micros血液分析儀通過任何方式進行連接。所有結(jié)果能夠被集中在同一屏幕的中央，自動或者人工進行驗證。

Horiba使用ABX Pentra120分析儀，整合了叫做Double Diff Matrix的獨特工藝。這種特性能夠顯著減低人工之間的差異，允許科學(xué)家首次能夠區(qū)別與白細胞生成相關(guān)的三種重要細胞系。Double Diff Matrix工藝聯(lián)合使用流式細胞技術(shù)與細胞化學(xué)技術(shù)，能夠常規(guī)鑒別與定量檢查3種在白細胞生成中未成熟的細胞系：粒細胞、淋巴細胞、單核細胞。由于真正反映檢測結(jié)果，重新檢查的切片數(shù)量得以減少，血液科醫(yī)生能夠得到快速報告從而能夠快速做出決定。ABX Pentra DF120每小時提供32種參數(shù)處理120例樣本，同時一個專家確認工作站能夠自動對結(jié)果進行確認以及驗證。
 
Multilink Speeds Hematology Analysis
 
A new multilink system allows up to three hematology analyzers to be connected to the same validation station, enabling hematology laboratories to handle up to 2,000 samples per day with configurations tailored to individual lab requirements.

The system, called ABX Pentra ML, is designed for use with the hematology analyzers of Horiba ABX (Montpellier, France). The ABX Pentra ML allows any model from the company’s ABX Pentra or Micros hematology analyzer line to be linked in any combination. All results can be centralized on the same screen to be validated automatically or manually.

Horiba has launched a new line of ABX Pentra 120 analyzers that incorporate exclusive technology called Double Diff Matrix. This feature significantly reduces manual differentials, enabling scientists for the first time to distinguish three key cell lines involved in leukopoiesis. Double Diff Matrix technology combines flow cytometry and cytochemistry to provide routine identification and quantification of the three immature lines involved in leukopoiesis: granulocytic, lymphocytic, and monocytic. Thanks to true reflex testing, the number of slide re-examinations is reduced and the hematologist receives a fast report enabling rapid decision-making. The ABX Pentra DF 120 offers 32 parameters and 120 samples per hour, while an expert validation station provides automatic confirmation and validation of results.